Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors

To determine the maximum‐tolerated duration and dose‐limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors.

[1]  N. Cheung,et al.  Oral Topotecan for Refractory and Relapsed Neuroblastoma: A Retrospective Analysis , 2003, Journal of pediatric hematology/oncology.

[2]  Eugene S. Kim,et al.  Topotecan is anti-angiogenic in experimental hepatoblastoma. , 2002, Journal of pediatric surgery.

[3]  Peter Bohlen,et al.  Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. , 2002, Cancer research.

[4]  Eugene S. Kim,et al.  Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. , 2002, Journal of pediatric surgery.

[5]  Takashi Tsuruo,et al.  Topotecan inhibits VEGF‐ and bFGF‐induced vascular endothelial cell migration via downregulation of the PI3K‐Akt signaling pathway , 2002, International journal of cancer.

[6]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  W. Middlesworth,et al.  Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. , 2001, Journal of pediatric surgery.

[8]  R. Kerbel,et al.  Antiangiogenic scheduling of lower dose cancer chemotherapy. , 2001, Cancer journal.

[9]  P. Meyers,et al.  Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. , 2000, Medical and pediatric oncology.

[10]  E Glatstein,et al.  High-time chemotherapy or high time for low dose. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Ellis,et al.  Chemotherapeutic drugs—more really is not better , 2000, Nature Medicine.

[12]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[13]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[14]  M. Harris,et al.  #465 Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group (POG) phase II study , 1999 .

[15]  D. Ribatti,et al.  Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. , 1999, Cancer research.

[16]  M. Cumming,et al.  Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.

[17]  M. Tan,et al.  Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors , 1999, Cancer Chemotherapy and Pharmacology.

[18]  H. Cohen,et al.  Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  A. Cnaan,et al.  Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. , 1998, Anti-cancer drugs.

[20]  C. Stewart,et al.  Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. McDowell,et al.  High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Zelterman,et al.  Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. D'Amato,et al.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.

[24]  L. Grochow,et al.  Factors Affecting Topotecan Sensitivity in Human Leukemia Samples a , 1996, Annals of the New York Academy of Sciences.

[25]  J. Kurtzberg,et al.  Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study , 1996, Journal of pediatric hematology/oncology.

[26]  S. Steinberg,et al.  Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors , 1996, Cancer.

[27]  E. Gehan,et al.  Cyclophosphamide Dose Escalation in Combination with Vincristine and Actinomycin‐D (VAC) in Gross Residual Sarcoma: A Pilot Study Without Hematopoietic Growth Factor Support Evaluating Toxicity and Response , 1995, Journal of pediatric hematology/oncology.

[28]  D. Venzon,et al.  A Phase I and II Trial of Dose‐Intensified Cyclophosphamide and GM‐CSF in Pediatric Malignant Brain Tumors , 1995, Journal of pediatric hematology/oncology.

[29]  N. Breslow,et al.  Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Furman,et al.  Phase I study of topotecan for pediatric patients with malignant solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Chatterjee,et al.  Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. , 1994, Oncology research.

[32]  F. Balis,et al.  Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. , 1993, Cancer research.

[33]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[34]  J. Champoux,et al.  Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. , 1992, Cancer research.

[35]  J. Shuster,et al.  Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Wang,et al.  Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. , 1989, Cancer research.

[37]  B. Teicher,et al.  Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. , 1989, Cancer research.

[38]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[39]  R. Saura,et al.  Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. , 1989, Arthritis and rheumatism.

[40]  T. Wagner,et al.  Pharmacokinetics of “activated” cyclophosphamide and therapeutic efficacies , 1984, Cancer.

[41]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.

[42]  M. D’Incalci,et al.  Decreased half life of cyclophosphamide in patients under continual treatment. , 1979, European journal of cancer.

[43]  J. Finklestein,et al.  Evaluation of a high dose cyclophosphamide regimen in childhood tumors , 1969, Cancer.